22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Active as of 2024-04-27

Generated Narrative: Citation

Resource Citation "179626" Version "1" Updated "2023-11-26 22:35:23+0000"

url: https://fevir.net/resources/Citation/179626

identifier: FEvIR Object Identifier/179626, https://pubmed.ncbi.nlm.nih.gov/22056152

version: 1.0.0-ballot

title: 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

status: active

date: 2024-04-27 20:42:39+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2012-01-03

lastReviewDate: 2022-03-21

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()

classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2011-11-08 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2011-11-08 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2012-01-04 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/22056152, https://www.ncbi.nlm.nih.gov/pmc//PMC3243932, https://doi.org/10.1016/S0140-6736(11)61095-7, pii/S0140-6736(11)61095-7
relatedIdentifier: ISRCTN24991896, https://clinicaltrials.gov/NCT00002633
Titles
- Type Language Text
* Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Abstracts
- Text Copyright
* **BACKGROUND:** Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such patients with locally advanced prostate cancer. **METHODS:** Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with either a prostate-specific antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL and a Gleason score of 8 or higher (n=25), were randomly assigned (done centrally with stratification and dynamic minimisation, not masked) to receive lifelong ADT and RT (65-69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes). The primary endpoint was overall survival. The results presented here are of an interim analysis planned for when two-thirds of the events for the final analysis were recorded. All efficacy analyses were done by intention to treat and were based on data from all patients. This trial is registered at controlledtrials.com as ISRCTN24991896 and Clinicaltrials.gov as NCT00002633. **RESULTS:** Between 1995 and 2005, 1205 patients were randomly assigned (602 in the ADT only group and 603 in the ADT and RT group); median follow-up was 6·0 years (IQR 4·4-8·0). At the time of analysis, a total of 320 patients had died, 175 in the ADT only group and 145 in the ADT and RT group. The addition of RT to ADT improved overall survival at 7 years (74%, 95% CI 70-78 vs 66%, 60-70; hazard ratio [HR] 0·77, 95% CI 0·61-0·98, p=0·033). Both toxicity and health-related quality-of-life results showed a small effect of RT on late gastrointestinal toxicity (rectal bleeding grade >3, three patients (0·5%) in the ADT only group, two (0·3%) in the ADT and RT group; diarrhoea grade >3, four patients (0·7%) vs eight (1·3%); urinary toxicity grade >3, 14 patients (2·3%) in both groups). **INTERPRETATION:** The benefits of combined modality treatment--ADT and RT--should be discussed with all patients with locally advanced prostate cancer. **FUNDING:** Canadian Cancer Society Research Institute, US National Cancer Institute, and UK Medical Research Council. Copyright © 2011 Elsevier Ltd. All rights reserved.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127:2893–2917.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/21351269/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/21351269
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20610543/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20610543
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146–8151.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/16278465/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/16278465
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010;28:557–567.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20816616/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20816616
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Fellows GJ, Clark PB, Beynon LL. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party—Subgroup on Prostatic Cancer. Br J Urol. 1992;70:304–309.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/1422689/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/1422689
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103–115.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/1100130/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/1100130
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/8433390/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/8433390
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/9426724/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/9426724
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Monti AF, Ostinelli A, Frigerio M. An ICRU 50 radiotherapy treatment chart. Radiother Oncol. 1995;35:145–150.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/7569023/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/7569023
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Bolla M, van Tienhoven G, Warde P. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066–1073.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20933466/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20933466
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Bolla M, Gonzalez D, Warde P. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/9233866/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/9233866
relatesTo
type: cites
citation: Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154.
relatesTo
type: cites
citation: Lan G, DeMets D. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Widmark A, Klepp O, Solberg A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19091394/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/19091394
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12:124–129.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/18647260/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/18647260
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41:280–287.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/15661554/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/15661554
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Bolla M, de Reijke TM, van Tienhoven G. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/19516032/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/19516032
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Horwitz EM, Bae K, Hanks GE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–2504.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/18413638/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/18413638
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Alibhai SM, Duong-Hua M, Cheung AM. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–923.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20643458/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20643458
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Alibhai SM, Mohamedali HZ. Cardiac and cognitive effects of androgen deprivation therapy: are they real? Curr Oncol. 2010;17(suppl 2):S55–S64.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20882135/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20882135
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/16983113/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/16983113
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/15647578/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/15647578
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: McMullen KP, Lee WR. A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. Urology. 2003;61:391–396.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/12597954/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/12597954
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Kuban DA, Tucker SL, Dong L. Long-term results of the M D Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/17765406/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/17765406
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Zietman AL, DeSilvio ML, Slater JD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/16160131/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/16160131
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol. 2010;7:31–38.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20062072/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20062072
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–1123.
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/20124165/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/20124165
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Lancet. 2011 Dec 17;378(9809):2056-7
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/22056154/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/22056154
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Ann Intern Med. 2012 Apr 17;156(8):JC4-05, JC4-04
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/22508745/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/22508745
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: J Urol. 2012 Sep;188(3):810
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/22883758/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/22883758
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2012 Nov;62(5):932-3
Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/23036346/
resourceReference: https://pubmed.ncbi.nlm.nih.gov/23036346
publicationForm
PublishedIns
- Type Identifier Title PublisherLocation
* Periodical (Published In Type#D020492) Electronic ISSN Type/1474-547X, ISOAbbreviation/Lancet, ISSN Linking/0140-6736, Medline Title Abbreviation/Lancet, NLM Unique ID/2985213R Lancet (London, England) England
citedMedium: Internet (Cited Medium#internet)
volume: 378
issue: 9809
articleDate: 2011-12-17
publicationDateText: 2011-Dec-17
language: English (Tags for the Identification of Languages#en)
pageString: 2104-11
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2011-11-02
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
url: https://pubmed.ncbi.nlm.nih.gov/22056152/
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
url: https://doi.org/10.1016/S0140-6736(11)61095-7
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Gonadotropin-Releasing Hormone (chemical-substances#33515-09-2; #D007987)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifactAssessment:

artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adenocarcinoma (#D000230)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
component
type: qualifier ()
classifier: therapy (#Q000628)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Combined Modality Therapy (#D003131)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: agonists (#Q000819)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
component
type: qualifier ()
classifier: therapy (#Q000628)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Quality of Life (#D011788)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Radiotherapy (#D011878)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Rate (#D015996)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial, Phase III (#D017428), Journal Article (#D016428), Multicenter Study (#D016448), Randomized Controlled Trial (#D016449), Research Support, N.I.H., Extramural (#D052061), Research Support, Non-U.S. Gov't (#D013485)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
contributor:

name: Padraig Warde
forenameInitials: P
affiliation: : Princess Margaret Hospital, Toronto, Canada. padraig.warde@rmp.uhn.on.ca
entry
contributor:

name: Malcolm Mason
forenameInitials: M
entry
contributor:

name: Keyue Ding
forenameInitials: K
entry
contributor:

name: Peter Kirkbride
forenameInitials: P
entry
contributor:

name: Michael Brundage
forenameInitials: M
entry
contributor:

name: Richard Cowan
forenameInitials: R
entry
contributor:

name: Mary Gospodarowicz
forenameInitials: M
entry
contributor:

name: Karen Sanders
forenameInitials: K
entry
contributor:

name: Edmund Kostashuk
forenameInitials: E
entry
contributor:

name: Greg Swanson
forenameInitials: G
entry
contributor:

name: Jim Barber
forenameInitials: J
entry
contributor:

name: Andrea Hiltz
forenameInitials: A
entry
contributor:

name: Mahesh K B Parmar
forenameInitials: MK
entry
contributor:

name: Jinka Sathya
forenameInitials: J
entry
contributor:

name: John Anderson
forenameInitials: J
entry
contributor:

name: Charles Hayter
forenameInitials: C
entry
contributor:

name: John Hetherington
forenameInitials: J
entry
contributor:

name: Matthew R Sydes
forenameInitials: MR
entry
contributor:

name: Wendy Parulekar
forenameInitials: W
entry
contributor:

name: NCIC CTG PR.3/MRC UK PR07 investigators

Generated Narrative: Practitioner #author0
name: Padraig Warde

Generated Narrative: Practitioner #author1
name: Malcolm Mason

Generated Narrative: Practitioner #author2
name: Keyue Ding

Generated Narrative: Practitioner #author3
name: Peter Kirkbride

Generated Narrative: Practitioner #author4
name: Michael Brundage

Generated Narrative: Practitioner #author5
name: Richard Cowan

Generated Narrative: Practitioner #author6
name: Mary Gospodarowicz

Generated Narrative: Practitioner #author7
name: Karen Sanders

Generated Narrative: Practitioner #author8
name: Edmund Kostashuk

Generated Narrative: Practitioner #author9
name: Greg Swanson

Generated Narrative: Practitioner #author10
name: Jim Barber

Generated Narrative: Practitioner #author11
name: Andrea Hiltz

Generated Narrative: Practitioner #author12
name: Mahesh K B Parmar

Generated Narrative: Practitioner #author13
name: Jinka Sathya

Generated Narrative: Practitioner #author14
name: John Anderson

Generated Narrative: Practitioner #author15
name: Charles Hayter

Generated Narrative: Practitioner #author16
name: John Hetherington

Generated Narrative: Practitioner #author17
name: Matthew R Sydes

Generated Narrative: Practitioner #author18
name: Wendy Parulekar

Generated Narrative: Organization #author19
name: NCIC CTG PR.3/MRC UK PR07 investigators

Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adenocarcinoma (#D000230)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
component
type: qualifier ()
classifier: therapy (#Q000628)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Combined Modality Therapy (#D003131)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Gonadotropin-Releasing Hormone (#D007987)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: agonists (#Q000819)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Orchiectomy (#D009919)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: radiotherapy (#Q000532)
component
component
type: qualifier ()
classifier: therapy (#Q000628)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Quality of Life (#D011788)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Radiotherapy (#D011878)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Rate (#D015996)
freeToShare: true
Components
- Type Classifier
* qualifier () is not a major topic ()